-
KALYDECO in Cystic Fibrosis receives positive CHMP opinion by EMA
- October 21, 2018
- Posted by: PharmaScroll
- Category:
No Comments -
Positive results from new triple combinations in Cystic Fibrosis, displayed by Vertex
- October 21, 2018
- Posted by: PharmaScroll
- Category:
-
FDA Approves ORKAMBI in Cystic Fibrosis for Children Ages 2-5 Years
- August 13, 2018
- Posted by: PharmaScroll
- Category:
-
Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis
- April 30, 2018
- Posted by: PharmaScroll
- Category: